Search Within

Maria Camila Pena velasquez

Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
  3. Review (1)
Groups
  1. Nursing (8)
  2. Department of Medicine (7)
  3. Center for Hematologic Malignancies (6)
  4. Hematologic Malignancies, Division of (6)
  5. Adult Leukemia (5)
  6. GME, Medicine (5)

More Groups

People
  1. Anthony Mato (5)
  2. Lindsey Roeker (5)
  3. Andrew Zelenetz (4)
  4. Meghan Thompson (4)
  5. Gail Panton (3)
  6. Sonia Lebowitz (3)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (5)
  4. 2021 (1)
Publications
  1. Blood (2)
  2. Clinical Cancer Research (1)
  3. Oncology Nursing Forum (1)
  4. Science (1)
  5. Supportive Care in Cancer (1)
  6. Therapeutic Advances in Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (2)
  2. American Association for Cancer Research (1)
  3. American Association for the Advancement of Science (1)
  4. Elsevier Inc. (1)
  5. Oncology Nursing Society (ONS) (1)
  6. Sage Publications (1)

More Publishers

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients
    Journal Article

    Gu, S.; Menzer, C.; Hay, J. L.; Pena, C.; Dusza, S.; Lacouture, M. E.; Markova, A.
    Supportive Care in Cancer (2023)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • The potential of pirtobrutinib in multiple B-cell malignancies
    Review

    Jensen, J. L.; Mato, A. R.; Pena, C.; Roeker, L. E.; Coombs, C. C.
    Therapeutic Advances in Hematology (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach
    Meeting Abstract

    Dorsey, C.; Falco, V.; Pena-Velasquez, C.; Lebowitz, S.; Purdom, M.; Panton, G.
    Oncology Nursing Forum (2022)

    Fulltext@MSK | Save
  • Real-time reflectance confocal microscopy of cutaneous graft-versus-host disease correlates with histopathology
    Journal Article

    Reingold, R. E.; Monnier, J.; Ardigò€, M.; Stoll, J. R.; Pena, M. C.; Nanda, J. K.; Dusza, S. W.; Ruiz, J. D.; Flynn, L.; Afrin, A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save